JP Morgan Chase
CORT icon

JP Morgan Chase’s Corcept Therapeutics CORT Stock Holding History

JP Morgan Chase’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.7M Buy
253,182
+52,229
+26% +$3.15M ﹤0.01% 2119
2026
Q1 		$7.66M Sell
200,953
-633,496
-76% -$23.7M ﹤0.01% 2925
2025
Q4 		$29M Sell
834,449
-15,415
-2% -$1.21M ﹤0.01% 1737
2025
Q3 		$70.6M Buy
849,864
+587,053
+223% +$42.5M ﹤0.01% 1185
2025
Q2 		$19.3M Sell
262,811
-27,964
-10% -$2.03M ﹤0.01% 1978
2025
Q1 		$33.2M Buy
290,775
+30,873
+12% +$1.88M ﹤0.01% 1542
2024
Q4 		$13.1M Buy
259,902
+6,832
+3% +$358K ﹤0.01% 2443
2024
Q3 		$11.7M Buy
253,070
+76,573
+43% +$2.72M ﹤0.01% 2474
2024
Q2 		$5.73M Sell
176,497
-17,074
-9% -$468K ﹤0.01% 2934
2024
Q1 		$4.88M Sell
193,571
-6,013
-3% -$142K ﹤0.01% 3130
2023
Q4 		$6.48M Buy
199,584
+7,000
+4% +$192K ﹤0.01% 2854
2023
Q3 		$5.25M Sell
192,584
-29,922
-13% -$866K ﹤0.01% 2809
2023
Q2 		$4.95M Sell
222,506
-68,086
-23% -$1.57M ﹤0.01% 2871
2023
Q1 		$6.29M Buy
290,592
+48,146
+20% +$1.06M ﹤0.01% 2640
2022
Q4 		$4.92M Buy
242,446
+10,435
+4% +$262K ﹤0.01% 2823
2022
Q3 		$5.95M Buy
232,011
+3,296
+1% +$88.2K ﹤0.01% 2593
2022
Q2 		$5.44M Buy
228,715
+12,634
+6% +$275K ﹤0.01% 2720
2022
Q1 		$4.87M Buy
216,081
+5,036
+2% +$107K ﹤0.01% 3028
2021
Q4 		$4.18M Sell
211,045
-313,577
-60% -$6.36M ﹤0.01% 3220
2021
Q3 		$10.3M Sell
524,622
-135,161
-20% -$2.83M ﹤0.01% 2359
2021
Q2 		$14.5M Buy
659,783
+469,589
+247% +$10.4M ﹤0.01% 2105
2021
Q1 		$4.53M Sell
190,194
-9,051
-5% -$242K ﹤0.01% 3054
2020
Q4 		$5.21M Buy
199,245
+92,892
+87% +$1.96M ﹤0.01% 2774
2020
Q3 		$1.87M Buy
106,353
+43,277
+69% +$690K ﹤0.01% 3281
2020
Q2 		$1.06M Buy
63,076
+22,544
+56% +$317K ﹤0.01% 3479
2020
Q1 		$483K Sell
40,532
-171
-0.4% -$2.12K ﹤0.01% 3830
2019
Q4 		$492K Buy
40,703
+3,689
+10% +$51.4K ﹤0.01% 4244
2019
Q3 		$524K Buy
37,014
+3,373
+10% +$41.4K ﹤0.01% 4154
2019
Q2 		$375K Sell
33,641
-122,033
-78% -$1.36M ﹤0.01% 4365
2019
Q1 		$1.83M Buy
155,674
+126,204
+428% +$1.57M ﹤0.01% 3395
2018
Q4 		$394K Sell
29,470
-81,939
-74% -$1.08M ﹤0.01% 4247
2018
Q3 		$1.56M Buy
111,409
+44,169
+66% +$617K ﹤0.01% 3634
2018
Q2 		$1.06M Sell
67,240
-160,518
-70% -$2.79M ﹤0.01% 3806
2018
Q1 		$3.75M Buy
227,758
+51,576
+29% +$956K ﹤0.01% 2810
2017
Q4 		$3.18M Buy
176,182
+172,046
+4,160% +$3.12M ﹤0.01% 3024
2017
Q3 		$79K Buy
4,136
+1,947
+89% +$29K ﹤0.01% 4361
2017
Q2 		$26K Sell
2,189
-9,758
-82% -$106K ﹤0.01% 4489
2017
Q1 		$131K Sell
11,947
-57,888
-83% -$508K ﹤0.01% 4224
2016
Q4 		$507K Buy
+69,835
New +$547K ﹤0.01% 3762
2013
Q4 		– Sell
-28,732
Closed -$46K – 4108
2013
Q3 		$46K Sell
28,732
-651
-2% -$1.15K ﹤0.01% 4270
2013
Q2 		$51K Buy
+29,383
New +$52.8K ﹤0.01% 4266

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's CORT Position: Q2 2026 in Review

JP Morgan Chase increased its Corcept Therapeutics (CORT) stake by 26% in Q2 2026, buying an estimated $3.15M and bringing the position to 253,182 shares worth $22.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2119.

JP Morgan Chase first reported a position in CORT in Q2 2013 and has held it in 41 quarters since. The position peaked at $70.6M in Q3 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • JP Morgan Chase held 253,182 shares of Corcept Therapeutics worth $22.7M as of Q2 2026.
  • JP Morgan Chase bought 52,229 Corcept Therapeutics shares in Q2 2026, an estimated $3.15M.
  • Corcept Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2119 holding.
  • JP Morgan Chase first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 41 quarters since.
  • JP Morgan Chase's Corcept Therapeutics position peaked at $70.6M in Q3 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.